Benzinga’s Top Upgrades, Downgrades For June 19, 2017

0 Comments 6 view(s)

Top Upgrades

  • Chardan Capital upgraded Clovis Oncology Inc (NASDAQ: CLVS) from Sell to Neutral. Clovis Oncology shares rose 47.6 percent to $88.50 in pre-market trading.

Latest Ratings for CLVS

Date Firm Action From To
Jun 2017 Chardan Capital Upgrades Sell Neutral
Jun 2017 Leerink Swann Initiates Coverage On Outperform
May 2017 JP Morgan Upgrades Neutral Overweight

View More Analyst Ratings for CLVS

View the Latest Analyst Ratings

read more